SEEL logoSEEL
Seelos Therapeutics Inc

26,077
Loading...
Loading...
News
all
press releases
Seelos Announces Second Postponement of its Annual Meeting of Stockholders
Seelos Announces Second Postponement of its Annual Meeting of Stockholders Seelos Announces Second Postponement of its Annual Meeting of Stockholders PR Newswire NEW YORK, Oct. 24, 2024 NEW YORK...
PR Newswire·11mo ago
News Placeholder
More News
News Placeholder
Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market
Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing...
PR Newswire·11mo ago
News Placeholder
Seelos Announces Postponement of its Annual Meeting of Stockholders
Seelos Announces Postponement of its Annual Meeting of Stockholders Seelos Announces Postponement of its Annual Meeting of Stockholders PR Newswire NEW YORK, Sept. 26, 2024 NEW YORK, Sept. 26, 2024...
PR Newswire·1y ago
News Placeholder
Seelos Therapeutics Announces 1-for-16 Reverse Stock Split
Seelos Therapeutics Announces 1-for-16 Reverse Stock Split Seelos Therapeutics Announces 1-for-16 Reverse Stock Split PR Newswire NEW YORK, Sept. 25, 2024 NEW YORK, Sept. 25, 2024 /PRNewswire...
PR Newswire·1y ago
News Placeholder
What's Going On With Seelos Therapeutics Stock Tuesday?
Seelos shares are trading higher Tuesday after the company announced that it signed a material transfer agreement to supply SLS-002 for the Department of Defense's Military and Veterans Adaptative...
Benzinga·1y ago
News Placeholder
Seelos Therapeutics announces the signing of a Material Transfer Agreement with U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate SLS-002 for treatment of PTSD
Seelos Therapeutics announces the signing of a Material Transfer Agreement with U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate SLS-002 for treatment of PTSD Seelos Therapeutics...
PR Newswire·1y ago
News Placeholder
Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules Seelos Therapeutics Announces Pricing of $1.1...
PR Newswire·1y ago
News Placeholder
Seelos Therapeutics Announces 1-for-8 Reverse Stock Split
Seelos Therapeutics Announces 1-for-8 Reverse Stock Split Seelos Therapeutics Announces 1-for-8 Reverse Stock Split PR Newswire NEW YORK, May 14, 2024 NEW YORK, May 14, 2024 /PRNewswire/ -- Seelos...
PR Newswire·1y ago
News Placeholder
Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations
Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations Seelos Therapeutics Announces...
PR Newswire·1y ago
News Placeholder
Seelos Therapeutics provides update on top-line data of Phase 2/3 trial
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·1y ago

Latest SEEL News

View

Advertisement. Remove ads.

Advertisement. Remove ads.